Etonogestrel for Birth Control (LACTO-Rod Trial)

"This clinical trial aims to evaluate the primary outcome of time-to-lactogenesis within 8 weeks postpartum, as well as secondary outcomes including Edinburgh Postnatal Depression Scale (EPDS) scores at 2, 4, 8, 12 and 24 weeks postpartum for assessing postpartum mood; a four point Likert scale questionnaire to compare factors associated with discontinuation of breastfeeding between immediate vs. standard groups; and an exclusive breastfeeding trichotomous question given in follow up questionnaires administered at 2,4,8,12 and 24 week intervals."

"Based on the Phase 4 status of Etonogestrel, our team has assigned a safety rating of 3. This signifies that this particular drug is approved for use in clinical practice."

"Initially investigated by VL Medi Oy in 2011, etonogestrel has now undergone 44 clinical trials. Currently there are 8 studies actively recruiting participants, primarily at sites located in Albuquerque, New mexico."

"Etonogestrel is an efficacious treatment for contraception, contraceptive implant therapy, and reproductive age management."

"This clinical trial is actively recruiting participants, as evidenced by the listing on clinicaltrials.gov which was first posted June 3rd 2019 and most recently updated August 4th 2022."

"Research into Etonogestrel began in 2011, with a trial sponsored by Merck Sharp & Dohme LLC. After the successful completion of this initial study involving 90 patients, Phase 4 drug approval was granted for the medication. At present there are 8 separate clinical trials being conducted in 59 cities and 5 countries utilizing Etonogestrel."

"Indeed, according to clinicaltrials.gov, this medical study is still actively seeking participants. Initially posted on June 3rd 2019 and updated as recently as August 4th 2022, the trial intends to recruit 150 patients from 2 different sites."